Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodal Ablation + Perioperative Tislelizumab and Chemotherapy in Resectable Stage II–IIIB NSCLC
ChiCTR2600125061Phase 3Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Pathological Complete Response Rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600125061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125061.